lasme-cel (UCART22)

About Cellectis

Cellectis is a French-American biotech leader focused on developing universal, allogeneic CAR T-cell therapies using its proprietary TALEN® gene-editing technology. The company's core strategy is to overcome the manufacturing complexity, high cost, and treatment delays associated with autologous CAR-Ts by creating 'off-the-shelf' products from healthy donor cells. Its most advanced candidate, lasme-cel (UCART22), has shown compelling Phase 1 efficacy and safety in relapsed/refractory B-ALL, triggering the initiation of a pivotal Phase 2 trial with a projected peak sales opportunity of ~$700M. Cellectis sustains its innovation through a strong IP estate and strategic partnerships with companies like Allogene and Servier.

Therapeutic Areas

Other Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL) Drugs